News

Pinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.

The review emphasized the importance of therapies that provide sustained visual outcomes, given the increasing incidence of nAMD among aging adults.

During this interview, Perkins described a recent landmark study which yielded some unique findings regarding pathogen-detection.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

SIRI emerged as a significant factor influencing acute gout attacks, shedding light on a prospective diagnostic tool.

The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.

An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.

While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.

The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

The guideline was developed by a multidisciplinary panel and consists of 11 conditional recommendations for the use of biomarkers in the management of Crohn disease.

Just more than a month after the FDA approved their first biosimilar to ustekinumab (Stelara), Bio-Thera Solutions announced positive results from their phase 3 trial of BAT2206

Real-world data shows extended intervals with both brolucizumab alone or alternating anti-VEGF treatment regimens after 12 and 18 months in nAMD eyes.

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

In an interview with HCPLive, Juliana Reed, MS, explains the pivotal role biosimilars play in healthcare and the barriers to access and adoption.

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

Pharmacokinetic exposure of the biosimilar insulin and reference product showed similarity, supporting the interchangeability between the two insulin aspart products.

The biosimilars month in review highlights top data demonstrating the efficacy of biosimilars for treating inflammatory bowel disease and plaque psoriasis, as well as trends in adopting biosimilars among patients and clinicians in the US.

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

There was no statistically significant difference in postoperative thromboembolic events and incident heparin-induced thrombocytopenia among patients treated with branded versus biosimilar enoxaparin.

Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.

Results showed similar rates of treatment persistence between the groups, with further analysis calling attention to a 40% price reduction in the cost of treatment in Australia due to reference pricing policies between biosimilars and originators.

Approximately one third of patients with temporomandibular disorders had comorbid fibromyalgia.

This new data align with the acknowledged necessity for a disruption of the itch–scratch cycle in moderate-to-severe AD treatment among patients.

Announced on December 04, 2023, the approved label changes allow for administration regardless of timing of proton pump administration and for administration 15 minutes before breakfast.

Results of a database search reveal the management of pain symptoms remains a continued source of frustration and an unmet need for patients with fibromyalgia.

The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.

Investigators ranked ChatGPT responses to healthcare professional-oriented questions about IBD as more useful and reliable than the model’s responses to patient-oriented questions.